Rabbit Polyclonal FSHR Antibody

The follicle-stimulating hormone receptor (FSHR), a G protein-coupled receptor predominantly expressed in ovarian granulosa cells and testicular Sertoli cells, plays a critical role in reproductive physiology by regulating gametogenesis and steroidogenesis. FSHR antibodies, either endogenous autoantibodies or therapeutic monoclonal antibodies, have garnered attention for their dual roles in pathology and clinical applications. In autoimmune contexts, anti-FSHR antibodies are implicated in infertility, ovarian insufficiency, or testicular dysfunction by disrupting FSH-mediated signaling pathways, though their prevalence and mechanisms remain understudied. Conversely, engineered FSHR-targeting antibodies are explored for therapeutic potential. For instance, blocking FSHR activity could suppress estrogen production in hormone-sensitive cancers or serve as a contraceptive by inhibiting follicular development. Additionally, FSHR’s restricted expression makes it a promising target for antibody-drug conjugates or imaging agents in reproductive cancers. Recent advances include monoclonal antibodies like ASPR-001 in preclinical studies for ovarian conditions. Challenges persist in balancing efficacy with safety, as unintended effects on reproductive tissues may arise. Research also focuses on leveraging FSHR antibodies as biomarkers for diagnosing autoimmune infertility or monitoring ovarian reserve. Overall, FSHR antibodies represent a dynamic intersection of reproductive immunology and targeted therapy, with ongoing studies aiming to translate mechanistic insights into diagnostic and therapeutic innovations.